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Abstract
: The coordinated regulation of cellular protein synthesis and degradation is essential for normal
cellular functioning. The ubiquitin proteasome system mediates the intracellular protein
degradation that is required for normal cellular homeostasis. The 26S proteasome is a multi-
enzyme protease that degrades redundant proteins; conversely, inhibition of proteasomal
degradation results in intracellular aggregation of unwanted proteins and cell death. This
observation led to the development of proteasome inhibitors as therapeutics for use in cancer. The
clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the first
proteasome inhibitor, bortezomib, for the treatment of relapsed/refractory multiple myeloma.
Although bortezomib represents a major advance in the treatment of this disease, it can be
associated with toxicity and the development of drug resistance. Importantly, extensive preclinical
studies suggest that combination therapies can both circumvent drug resistance and reduce
toxicity. In addition, promising novel proteasome inhibitors, which are distinct from bortezomib,
and exhibit equipotent anti-multiple myeloma activities, are undergoing clinical evaluation in order
to improve patient outcome in multiple myeloma.
Publication history: Republished from Current BioData's Targeted Proteins database (TPdb;
http://www.targetedproteinsdb.com).
Protein pathway involvement in disease
The ubiquitin proteasome system (UPS)
Intracellular protein degradation occurs primarily
through a multisubunit complex called the proteasome
[1-3]. Pioneering studies by Ciechanover et al. showed
that ATP-dependent conjugation of proteins with a
polypeptide, ubiquitin (UBIQ), is required for protein
degradation [4-7]. Subsequent reports demonstrated the
role of UBIQ in cellular protein turnover [8,9], and it is
now well established that ubiquitylation of proteins
accounts for their stability, functionality, localization and
interactive capabilities [10].
UBIQ-mediated proteolysis occurs via the 26S proteas-
ome complex [11-15], which contains 19S units flanking
a barrel-shaped 20S proteasome core [16,17]; the 19S
units regulate entry of ubiquitylated proteins into the 20S
core chamber [2,18,19]. Protein breakdown involves
sequential enzymatic reactions that culminate in target
proteins becoming linked to a chain of UBIQ molecules.
In the first reaction, the E1 ubiquitin enzyme activates
UBIQ and attaches it to the ubiquitin-conjugating enzyme
E2 in an ATP-dependent manner. The E3 ubiquitin ligase
then links the UBIQ molecule to the target protein or to a
previously attached UBIQ moiety [20]. Sequential cycles
of this process lead to the formation of polyubiquitylated
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proteins that are eventually degraded by the proteasomes
into small peptides, with re-cycling of free UBIQ [21-24].
Importantly, E3 ubiquitin ligases confer specificity in the
UBIQ signaling pathway by selectively targeting potential
protein substrates for ubiquitylation and subsequent pro-
teasomal degradation [25]. Three proteasomal activities
that regulate proteolysis are chymotrypsin-like (CT-L),
trypsin-like (T-L) and caspase-like (C-L), also known as
β5, β2 and β1, respectively; all of these reside within the
20S proteasome core [26-28].
Proteolysis is a normal cellular process and thus substrates
for proteasomes include many cellular proteins that main-
tain normal cell cycle progression, growth and survival
[1,2,8,29-31]. Conversely, pharmacological inhibition of
proteasome function hampers the normal elimination of
misfolded proteins, thereby causing a build-up of
unwanted proteins and eventual cell death [32-34]. These
laboratory observations have translated into the clinical
application of proteasome inhibitors as anticancer thera-
pies. However, since the proteasome regulates normal cel-
lular functions, its inhibition could also trigger toxicity
against normal cells [33,35,36]. Importantly, recent stud-
ies have shown that proteasome inhibitors are more cyto-
toxic to proliferating malignant cells than quiescent
normal cells, suggesting a favorable therapeutic index [35-
41].
Targeting the UPS in multiple myeloma
As stated in the section The ubiquitin proteasome system
(UPS), a broad spectrum of intracellular proteins are sub-
strates for proteasome-mediated degradation. This proc-
ess involves NFκB, a transcription factor that plays a
pivotal role in the inflammatory response and carcinogen-
esis by controlling genes involved in growth, survival, cell
cycle progression, angiogenesis and invasion [42-44]. Pal-
ombella et al. showed that the UPS is required for process-
ing the NFKB1 (NFκB1) precursor protein and for
activation of NFκB [45]. Conversely, inhibition of protea-
somes by proteasome inhibitor MG132 blocked NFκB
activity [46]. Importantly, our studies showed that adhe-
sion of MM cells to bone marrow stromal cells (BMSCs)
triggered transcription and secretion of various cytokines
that confer growth, survival and drug resistance in MM
cells [47,48]. Other studies further confirmed the role of
NFκB as a major growth and survival signaling pathway in
MM [49-53]. The survival- and growth-promoting role of
NFκB in MM, together with the ability of proteasome
inhibitors to block NFκB, provided the initial rationale for
proteasome inhibitor therapy in MM. Studies by Pal-
ombella et al. focused on the development of a series of
peptide boronic acid inhibitors of the proteasome, in par-
ticular bortezomib, and demonstrated their inhibitory
activity on NFκB [46]. The dipeptidyl boronic acid borte-
zomib is a potent and reversible inhibitor of the CT-L
activity of the proteasome [33,41]. Initial NCI screening
showed the remarkable antitumor activity of bortezomib
against a panel of 60 tumor cell lines [41,54]. Our in vitro
studies showed that bortezomib downregulates NFκB,
blocks constitutive and MM cell adhesion-induced
cytokine secretion in BMSCs and induces apoptosis in
both MM cell lines and freshly isolated MM cells from
patients [35,51]. Moreover, in vivo studies using animal
models (see Disease models,  knockouts,  assays) demon-
strated a potent anti-MM activity of bortezomib [36,55].
Disease models, knockouts, assays
Our in vitro findings have also been validated in vivo using
animal models. These models represent an indispensable
bridge between basic research and clinical drug develop-
ment and have been extensively used in the validation of
bortezomib and other novel compounds against MM [55-
57]. One of the first models to be used was the human
plasmacytoma xenograft model, in which triple immuno-
deficient mice (beige-nude-xid) were injected subcutane-
ously with MM cells [55]. This model allows us to
simultaneously measure the effect of in vivo drug treat-
ment on the growth of human MM cells (assessed by
tumor cell size, human idiotypic protein in mouse serum
and host survival), as well as the neighboring blood ves-
sels (assessed by microvessel density). Our studies using
this model showed that bortezomib inhibits both human
MM cell growth and associated angiogenesis in vivo [55].
Although the human plasmacytoma xenograft model
allows for direct assessment of therapy of tumor growth
and associated angiogenesis, it does not reflect the bone
marrow milieu. For these studies, we have utilized the
SCID-hu mouse model developed in our laboratory [58].
This model examines MM cell growth in the human bone
marrow milieu, which includes human BMSCs, extracel-
lular matrix proteins and cytokines, and best reflects the
human disease [58-60]. In this model, MM cells are
injected directly into human fetal bone chips implanted
subcutaneously in SCID mice. Tumor growth is assessed
by evaluating circulating levels of soluble human IL6R
and human monoclonal antibody levels using ELISA [57].
This model allows us to perform immunohistochemical
analysis of excised human bone chips in order to deter-
mine MM cell growth in vivo using staining with antibod-
ies specific for tumor cells (SYND1 [CD138]).
Immunohistochemical analysis of human bone sections
from mice treated with various drugs, such as bortezomib,
lenalidomide or NPI-0052, can be performed to detect
apoptosis (CASP3 [caspase-3] activity, TUNEL staining),
growth inhibition (Ki67) and angiogenesis (PECA1
[CD31] and FA8 [Factor VIII staining]). ELISA and human
cytokine bead arrays are utilized for analyzing the effect of
drugs on human cytokine secretion in mouse serum trig-
gered by human MM-BMSC interactions. This modelBMC Biochemistry 2008, 9(Suppl 1):S1 http://www.biomedcentral.com/1471-2091/9/S1/S1
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therefore permits the evaluation of the molecular and cel-
lular changes induced by human MM-human stroma
interactions in vivo, before and after therapy. We have used
this model to validate novel targeted therapies such as
CD-138-DM1 antibody [57] and BAFF inhibitor [61]. Our
ongoing studies are examining the effects of various pro-
teasome inhibitors in this model.
Validation of the proteasome as a target for antineoplastic
therapy has led to the development of assays that not only
quantify the bulk of the proteasomes in cells, but also
qualitatively assess their function [3,28]. Given the differ-
ential proteolytic activities of the proteasome and the
growing number of available inhibitors, it is essential to
establish a relationship between the effectiveness of the
drugs and the extent and type of proteasomal blockade.
Fluorogenic peptide substrates specific for each proteaso-
mal subunit provide a rapid, sensitive and accurate tool
for assessing residual proteasomal activity in crude lysates
[62]. Although extremely useful, these probes require
prior cell lysis, thus isolating the proteasome from its
functional, regulatory environment [63]. Moreover, fluor-
ogenic substrates do not differentiate between constitu-
tive and interferon-inducible (immunoproteasome)
proteasomal activities [63]. These limitations have
aroused interest in designing cell permeable, specific pro-
teasome probes, such as DansylAhx3L3VS, capable of
monitoring proteasome activity in living cells [64].
DansylAhx3L3VS has been proven to be useful for defining
the differential activity profiles of the two proteasome
inhibitors bortezomib and NPI0052 in MM cell lines [36].
It was also effective in differentiating between the inhibi-
tion of constitutive and inducible proteasomal activity in
peripheral blood mononuclear cells from patients under-
going treatment with bortezomib [65]. These experiments
confirm the use of DansylAhx3L3VS for quantitatively and
qualitatively monitoring proteasomal blockade in
patients receiving proteasome inhibitor therapy [65].
Disease targets and ligands
Preclinical studies provided the basis for the evaluation of
bortezomib as a therapy in MM. A Phase I clinical trial on
27 patients with refractory hematologic malignancies
showed anti-MM activity and acceptable toxicity, and in a
Phase II trial enrolling 202 relapsed, refractory MM
patients, one third of the patients achieved durable
responses (with 4% complete responses) and associated
clinical benefit. This provided the basis for accelerated
FDA approval of bortezomib treatment for relapsed
refractory MM [66,67]. Thereafter, a randomized Phase III
trial on 669 MM patients who had relapsed after at least
one prior treatment showed higher responses, as well as
prolonged time to progression and survival, after treat-
ment with bortezomib when compared with dexametha-
sone [68]. This provided the basis for the extension of
FDA approval of bortezomib to include treatment of
relapsed MM. Despite the success of bortezomib therapy
(43% objective response rates), it has been associated
with possible off-target toxicities and the development of
drug resistance [67,69-72]. Therefore, extensive labora-
tory efforts are now focused on delineating the molecular
mechanisms mediating bortezomib cytotoxicity and drug
resistance, in order to both enhance sensitivity and over-
come clinical resistance to bortezomib.
Mechanistic insights into bortezomib-induced cell death
Bortezomib-triggered apoptosis in MM cells is associated
with inhibition of NFκB; however, whether NFκB block-
ade is an obligatory event remains unclear. To address this
issue, we compared the effects of PS1145, a specific inhib-
itor of IKKB (IKK-B), with the effects of bortezomib on
NFκB and consequent biological response (cell death) in
MM cells. Both PS1145 and bortezomib block TNFA
(TNF-α)-induced NFκB activation by inhibiting phospho-
rylation and degradation of IKKB. However, in contrast to
bortezomib, PS1145 only partially inhibits MM cell
growth [50]. These findings showed that NFκB inhibition
alone is unlikely to account for the overall anti-MM activ-
ity of bortezomib. Supportive of these findings, studies to
date suggest that bortezomib affects both growth and
apoptotic signaling pathways. For example, bortezomib-
triggered apoptosis is associated with: activation of heat
shock proteins (HSPB1 [Hsp27], Hsp70 and Hsp90)
[73,74]; upregulation of JNK/SAPK [73,75,76]; generation
of reactive oxygen species [77]; release of CYC (cyto-
chrome-c)/DBLOH (Smac) from mitochondria into the
cytosol and activation of CASP9 (caspase-9) and CASP3
(caspase-3) [75,76]; activation of BIM (Bim) and CASP8
(caspase-8) [73,76]; blockade of DNA repair [78]; inhibi-
tion of MM-BMSC interactions and sequelae including
activation of MAPK and PI3K signaling pathways [35,79],
and induction of ER stress and an unfolded protein
response [80,81]. Together, these in vitro studies suggest
that proteasome inhibition by bortezomib triggers both
various apoptotic signaling cascades and blocks growth/
survival mechanisms in MM cells [82].
New frontiers in drug discovery
Oncogenomics and proteomic studies in MM cells are
identifying and validating key molecules, the pharmaco-
logical inhibition of which enhances the antitumor activ-
ity of bortezomib and could abrogate drug resistance [83].
Firstly, bortezomib induces Hsp90 in MM cells, whereas
blockade of Hsp90 with 17AAG (Kosan Biosciences, USA)
enhances sensitivity and even overcomes resistance to
bortezomib [84]. Ongoing clinical trials show that combi-
nation therapy can achieve responses in refractory MM
[85]. Secondly, laboratory studies show that bortezomib
induces HSPB1 (Hsp27), and MM cells from patients
resistant to bortezomib overexpress HSPB1 [74,86]. TheseBMC Biochemistry 2008, 9(Suppl 1):S1 http://www.biomedcentral.com/1471-2091/9/S1/S1
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findings have already been tested in a clinical trial by com-
bining bortezomib with a p38 MAPK inhibitor,
SCIOS469 (Scios USA), which downregulates HSPB1 and
overcomes bortezomib resistance [87,88]. Thirdly, treat-
ment of MM cell lines and SYND1 (CD138)+ MM cells
with bortezomib and the novel agents lenalidomide
(immunomodulatory agent from Celgene, USA) or
CDDO-Imidazolide (a triterpenoid initially synthesized
by Honda et al., Dartmouth College, USA) induces syner-
gistic anti-MM activity in vitro and overcomes resistance to
bortezomib by targeting both intrinsic and extrinsic apop-
totic signaling. This was evidenced by the disruption of
mitochondrial potential and cleavage of CASP9 (caspase-
9) and CASP8 (caspase-8) [89,90]. These in vitro studies
provide the basis for clinical protocols combining these
agents [91]. Fourth, bortezomib combined with conven-
tional anti-MM agents such as dexamethasone (Merck
USA), doxorubicin (Pharmacia S.p.A, Italy), melphalan
(GlaxoSmithKline, UK) or mitoxantrone (Lederle
Parenterals, Puerto Rico) induces additive or synergistic
antitumor activity in MM cell lines and freshly isolated
SYND1+ MM cells, as measured by decreased cell viability
in colorimetric assays (MTT assay) [78].
A recent randomized Phase III trial in 646 patients
showed that treatment with pegylated doxorubicin and
bortezomib achieved increased overall survival and extent
of responses, as well as prolonged time to progression,
compared with bortezomib alone. This provided the
rationale for FDA approval of this combination for the
treatment of relapsed MM [92,93]. Finally, our preclinical
studies showed that the simultaneous targeting of lyso-
somal and proteasomal (non-lysosomal mechanism) pro-
tein degradation triggers synergistic anti-MM activity
[94,95]. For example, HDAC6 (HDAC-6) is required for
the chaperoning of ubiquitylated proteins for aggresomal
degradation. Simultaneous inhibition of proteasomes
and aggresomes with bortezomib and tubacin (HDAC6
inhibitor) induces synergistic cytotoxicity in MM cell lines
and primary cells from MM patients [95]. A recent study
in pancreatic cancer cells showed that bortezomib trig-
gered the formation of aggresomes (aggregates of ubiqui-
tin-conjugated proteins), which are cytoprotective,
whereas their disruption by HDAC6 siRNA induced syner-
gistic apoptosis [96]. These findings set the stage for the
evaluation of combined treatment protocols of borte-
zomib with HDAC inhibitors in both hematologic malig-
nancies and solid tumors. Our study has already validated
the anti-MM activity of HDAC inhibitor LBH589
(Novartis Pharmaceuticals, USA) [97]; and a Phase I safety
study of LBH589, given in combination with bortezomib,
is ongoing in MM patients [98].
Discovery and validation of novel proteasome inhibitors 
NPI0052 and PR171 as therapy
A recent study showed that a novel proteasome inhibitor,
NPI0052 (salinosporamide A), is able to overcome borte-
zomib resistance in MM cells. NPI0052 is a small mole-
cule derived from the fermentation of Salinospora, a
marine gram-positive actinomycete [36,99,100].
NPI0052 is a nonpeptide proteasome inhibitor with struc-
tural similarity to omuralide. Omuralide is clasto-lacta-
cystin beta-lactone and is the active form of a proteasome
inhibitor, lactacystin [82]. Despite the structural similarity
with omuralide, NPI0052 can be distinguished by the
presence of a uniquely methylated C3 RING juncture,
chlorinated alkyl group at C2 and a cyclohexene ring at C5
[82,99-101]. Initial screening of NPI0052 against the NCI
panel of 60 tumor cell lines showed an IC50 of < 10 nM in
all cases. Importantly, NPI0052 similarly triggered apop-
tosis in purified tumor cells from several MM patients
relapsing after prior therapies including bortezomib and
thalidomide [36]. In vivo efficacy of NPI0052 was shown
using a human plasmacytoma xenograft mouse model.
Specifically, NPI0052 inhibited MM tumor growth and
prolonged survival of these mice at concentrations that
were well tolerated, without weight loss or neurological
changes [36,55]. Another study showed that NPI0052 is a
more effective inducer of apoptosis than bortezomib in
lymphocytic leukemic cells [102].
Examination of signal transduction pathways in MM cells
showed that: NPI0052 is a more potent inhibitor of NFκB
and related cytokine transcription and secretion than
bortezomib; NPI0052-induced MM cell death is predom-
inantly mediated by CASP8 and bortezomib-induced
apoptosis requires both CASP8 and CASP9 activation
[36]. Moreover, NPI0052 and bortezomib differentially
affect 20S proteasomal activities; NPI0052 inhibits all
three proteasomal activities, i.e. CT-L, T-L and C-L,
whereas bortezomib blocks CT-L and C-L but not T-L
activities [36]. A recent study showed that simultaneous
inhibition of multiple proteasome activities is a prerequi-
site for significant (i.e. > 50%) proteolysis [62]. Another
study showed that 50% inhibition of CFTR degradation in
reticulocyte extracts requires concurrent blockade of CT-L
and C-L proteasome activities [103]. Whether blocking all
three activities is therapeutically advantageous will be
evaluated in clinical trials of NPI0052. Nonetheless, the
mechanistic differences between NPI0052 and borte-
zomib, i.e. their differential effect on proteasome activi-
ties and their dependence on specific apoptotic signal
transduction pathways, provides a rationale for combina-
tion proteasome inhibitor regimens to enhance MM cyto-
toxicity. Indeed, the combination of NPI0052 with
bortezomib induces synergistic anti-MM activity, without
significantly affecting the viability of normal lymphocytes
[36]. Enhanced cytotoxicity of the combination regimenBMC Biochemistry 2008, 9(Suppl 1):S1 http://www.biomedcentral.com/1471-2091/9/S1/S1
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could be due to higher levels of proteasome inhibition
with the two drug regimens and/or activation of differen-
tial apoptotic signaling pathways. Nevertheless, these pre-
liminary studies set the stage for clinical trials of
combined proteasome inhibitors to improve patient out-
come in MM.
Finally, PR171 or carfilzomib (Proteolix, USA) is another
novel proteasome inhibitor. PR171 [104-106] is an irre-
versible proteasome inhibitor, predominantly targeting
CT-L activity and triggering potent antitumor activity
[104,105]. A Phase I trial demonstrated tolerability and
responses [107] and Phase II trails are ongoing in
relapsed/refractory MM [108]. Laboratory studies are cur-
rently examining whether PR171 can be combined with
bortezomib to induce synergistic cytotoxicity in MM cells.
Conclusion
Delineation of the molecular and cellular mechanisms of
bortezomib-induced apoptosis [79,109] has provided the
rationale for combining bortezomib with conventional
(dexamethasone, doxorubicin, melphalan) and novel
(lenalidomide, HSP inhibitors, HDAC inhibitors) agents
in order to reduce toxicity, enhance cytotoxicity and over-
come drug resistance. Although bortezomib and NPI0052
belong to the same class of drugs, they are distinct in their
mode of action and can be rationally combined as therapy
[36,102,110]. The synergy observed in preliminary stud-
ies suggests an increased therapeutic index of combined
therapy. However, more definitive evidence of enhanced
efficacy of this combination regimen awaits careful clini-
cal trials.
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